Gm9 glucose analyser

Sonora Quest performed the screening laboratory tests and metabolic panel. Plasma glucose concentration was determined by the glucose oxidase method on the GM9 Glucose Analyser (Analox Instruments, Stourbridge, UK). Serum insulin was measured by an ELISA (Alpco, Salem, NH, USA). The enrichment of plasma glucose with 6,6 di-deuterated glucose was assayed using GC/MS in the Center for Clinical and Translational Science (CCaTS) Metabolomics Core at the Mayo Clinic in Rochester.

Routine biochemical analyses were performed at the clinical laboratory of the University Hospital of Pisa.
Plasma glucose was measured immediately during the MMTT by a GM9 Glucose Analyser (Analox Instruments, Stourbridge, UK). Plasma insulin, C-peptide, NEFA, glucagon, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) were measured in a single assay at the completion of the study at the Laboratory of Nutrition, Metabolism, and Atherosclerosis of the University of Pisa. Insulin and C-peptide measurements were performed by electrochemiluminescence on a COBAS e411 instrument (Roche, Indianapolis, IN, USA). Plasma NEFA levels were assayed by standard spectrophotometric methods (Synchron UniCel DxC 600, Beckman Instruments, Fullerton, CA, USA). Glucagon was measured by ELISA (Mercodia, Uppsala, Sweden). GLP-1 and GIP were measured by ELISA (Merck, Darmstadt, Germany).